

## Publications Relating to GDUFA Science and Research in Fiscal Year 2021

---

1. Amini E, Kurumaddali A, Bhagwat S, Berger S, and Hochhaus G. *Optimization of the Transwell® System for Assessing the Dissolution Behavior of Orally Inhaled Drug Products through In Vitro and In Silico Approaches*. *Pharmaceutics*. 13(8): 1109. <https://doi.org/10.3390/pharmaceutics13081109>. PMID: [34452069](https://pubmed.ncbi.nlm.nih.gov/34452069/).
2. Bajaj R, Chong L, Zou L, Tsakalozou E, Ni Z, Giacomini K, and Kroetz D. *Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein*. *AAPS Journal*. 23(5): 106. <https://doi.org/10.1208/s12248-021-00631-8>. PMID: [34528148](https://pubmed.ncbi.nlm.nih.gov/34528148/).
3. Bao Q, Zou Y, Wang Y, Choi S, and Burgess D. *Impact of Formulation Parameters on In Vitro Release from Long-Acting Injectable Suspensions*. *The AAPS Journal*. (2021) 23(2): 42. <https://doi.org/10.1208/s12248-021-00566-0>. PMID: [33709196](https://pubmed.ncbi.nlm.nih.gov/33709196/).
4. Beig A, Feng L, Walker J, Ackermann R, Hong J, Li T, Wang Y, and Schwendeman S. *Development and characterization of composition-equivalent formulations to the Sandostatin LAR® by the solvent evaporation method*. *Drug Delivery and Translational Research*. . <https://doi.org/10.1007/s13346-021-01013-5>. PMID: [34215997](https://pubmed.ncbi.nlm.nih.gov/34215997/).
5. Blume H, Mehta M, Beuerle G, Dorantes A, Hempel G, Jiang W, Kovar A, Lee J, Potthast H, Schug B, Seidlitz A, Tampal N, Tsang Y, Walstab J, and Welink J. *The Global Bioequivalence Harmonisation Initiative (GBHI): Report of the European Federation of Pharmaceutical Sciences (EUFEPS)/the American Association of Pharmaceutical Scientists (AAPS) fourth conference*. *European Journal of Pharmaceutical Sciences*. 167. <https://doi.org/10.1016/j.ejps.2021.105987>. PMID: [34481066](https://pubmed.ncbi.nlm.nih.gov/34481066/).
6. Brandis J, Kihn K, Taraban M, Schnorr J, Confer A, Batelu S, Sun D, Rodriguez J, Jiang W, Goldberg D, Langguth P, Stemmler T, Yu Y, Kane M, Polli J, and Michel S. *Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate*. *Molecular Pharmaceutics*. (2021) 18(4): 1544-1557. <https://doi.org/10.1021/acs.molpharmaceut.0c00922>. PMID: [33621099](https://pubmed.ncbi.nlm.nih.gov/33621099/).
7. Brito J, Ross J, Deng Y, Sangaralingham L, Graham D, Qiang Y, Wang Z, Yao X, Zhao L, Smallridge R, Bernet V, Shah N, and Lipska K. *Cardiovascular Outcomes and Rates of Fractures and Falls among Patients with Brand-name Versus Generic L-thyroxine Use*. *Endocrine*. (2021) 74(3):592-602 . <https://doi.org/10.1007/s12020-021-02779-x>. PMID: [34089480](https://pubmed.ncbi.nlm.nih.gov/34089480/).
8. Chari S, Sridhar K, Walenga R, and Kleinstreuer C. *Computational Analysis of a 3D Mucociliary Clearance Model Predicting Nasal Drug Uptake*. *Journal of Aerosol Science*. (2021) 155: Article 105757. <https://doi.org/10.1016/j.jaerosci.2021.105757>.
9. Dhapare S, Newman B, Svensson M, Elfman P, Sandell D, Winner L, Bulitta J, and Hochhaus G. *Factors Influencing Plume Characteristics of Metered Dose Inhalers (MDIs) Following Passage Through Bio-relevant Mouth-Throat Models*. *Respiratory Drug Delivery*. 1: 301-306.
10. Donnelly M, Tsakalozou E, Sharan S, Straubinger T, Bies R, and Zhao L. *Review of Complex Generic Drugs Delivered Through the Female Reproductive Tract: The Current Competitive Landscape and Emerging Role of Physiologically Based Pharmacokinetic Modeling to Support Development and Regulatory Decisions*. *Journal of Clinical Pharmacology*. (2020) 60(S2): S26-S33. <https://doi.org/10.1002/jcph.1760>. PMID: [33274513](https://pubmed.ncbi.nlm.nih.gov/33274513/).
11. Evans C, Hermsmeier M, Yamamoto A, and Chan K. *Visualizing Topical Drug Uptake with Conventional Fluorescence Microscopy and Deep Learning*. *Biomedical Optics Express*. (2020) 11(12): 6864-6880. <https://doi.org/10.1364/BOE.405502>. PMID: [33408967](https://pubmed.ncbi.nlm.nih.gov/33408967/).
12. Fang L, Song X, Ji P, Wang Y, Maynard J, Yim S, Sahajwalla C, Xu M, Kim M, and Zhao L. *Impact of Sex on Clinical Response in Rheumatoid Arthritis Patients Treated With Biologics at Approved Dosing*

- Regimens*. Journal of Clinical Pharmacology. 60(S2): S103-S109. <https://doi.org/DOI:10.1002/jcph.1776>. PMID: 33274512.
13. Fang L, Uppoor R, Xu M, Sharan S, Zhu H, Tampal N, Li B, Zhang L, Lionberger R, and Zhao L. *Use of Partial Area Under the Curve in Bioavailability or Bioequivalence Assessments: A Regulatory Perspective*. Clinical Pharmacology and Therapeutics. (2021) 110(4): 880-887. <https://doi.org/10.1002/cpt.2174>. PMID: 33492710.
  14. Farhan N, Cristofolletti R, Basu S, Kim S, Lingineni K, Jiang S, Brown J, Fang L, Lesko L, and Schmidt S. *Physiologically Based Pharmacokinetics Modeling to Investigate Formulation Factors Influencing the Generic Substitution of Dabigatran Etxilate*. CPT: Pharmacometrics & Systems Pharmacology. (2021) 10(3): 199-210. <https://doi.org/10.1002/psp4.12589>. PMID: 33449439.
  15. Farias G, Shur J, Price R, Bielski E, and Newman B. *A Systematic Approach in the Development of the Morphologically-Directed Raman Spectroscopy Methodology for Characterizing Nasal Suspension Drug Products*. AAPS Journal. 23(4): 73. <https://doi.org/10.1208/s12248-021-00605-w>. PMID: 34008082.
  16. Florian J, Matta M, Depalma R, Gershuny V, Patel V, Hsiao C, Zusterzeel R, Rouse R, Prentice K, Nalepinski C, Kim I, Yi S, Zhao L, Yoon M, Selaya S, Keire D, and Korvick J. *Effect of Oral Ranitidine on Urinary Excretion of N-Nitrosodimethylamine (NDMA)*. JAMA. 326(3): 240-249. <https://doi.org/10.1001/jama.2021.9199>. PMID: 34180947.
  17. Garner J, Skidmore S, Hadar J, Park H, Park K, Jhon Y, Qin B, and Wang Y. *Analysis of Semi-Solvent Effects for PLGA Polymers*. International Journal of Pharmaceutics. (2021) 602. <https://doi.org/10.1016/j.ijpharm.2021.120627>. PMID: 33915188.
  18. Gu J, Wang J, Krishna A, Xu L, Stewart S, Wang Y, Faustino P, and Shakleya D. *Simultaneous Quantification of Dexamethasone and 6 $\beta$ -hydroxydexamethasone in Rabbit Plasma, Aqueous and Vitreous Humor, and Retina by UHPLC-MS/MS*. Bioanalysis. (2021) 13(13): 1051-1062. <https://doi.org/10.4155/bio-2021-0088>. PMID: 34100308.
  19. Hamadeh A, Troutman J, and Edginton A. *Assessment of Vehicle Volatility and Deposition Layer Thickness in Skin Penetration Models*. Pharmaceutics. (2021) 13(6): 807. <https://doi.org/10.3390/pharmaceutics13060807>. PMID: 34071572.
  20. Hochhaus G, Chen M, Kurumaddali A, Schilling U, Jiao Y, Drescher S, Amini E, Kandala B, Tabulov C, Shao J, Seay B, Abu-Hasan M, Baumstein S, Winner L, Shur J, Price R, Hindle M, Wei X, Carrasco C, Sandell D, Oguntimein O, Kinjo M, Delvadia R, Saluja B, Lee S, Conti D, and Bulitta J. *Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?*. The AAPS Journal. (2021) 23(3): 48. <https://doi.org/10.1208/s12248-021-00569-x>. PMID: 33768368.
  21. Hsieh N, Bois F, Tsakalozou E, Ni Z, Yoon M, Sun W, Klein M, Reisfeld B, and Chiu W. *A Bayesian Population Physiologically Based Pharmacokinetic Absorption Modeling Approach to Support Generic Drug Development: Application to Bupropion Hydrochloride Oral Dosage Forms*. Journal of Pharmacokinetics and Pharmacodynamics. . <https://doi.org/10.1007/s10928-021-09778-5>. PMID: 34553275.
  22. Hsieh N, Reisfeld B, and Chiu W. *pk sensi: An R Package to Apply Global Sensitivity Analysis in Physiologically Based Kinetic Modeling*. Software X. 12. <https://doi.org/10.1016/j.softx.2020.100609>. PMID: 33426260.
  23. Jean D, Naik K, Milligan L, Hall S, Huang S, Isoherranen N, Kuemmel C, Seo P, Tegenge M, Wang Y, Yang Y, Zhang X, Zhao L, Zhao P, Benjamin J, Bergman K, Grillo J, Madabushi R, Wu F, Zhu H, and Zineh I. *Development of Best Practices in Physiologically Based Pharmacokinetic Modeling to Support Clinical Pharmacology Regulatory Decision-making—A Workshop Summary*. CPT: Pharmacometrics & Systems Pharmacology. (2021) 48(6): 893-908. <https://doi.org/10.1002/psp4.12706>. PMID: 34536337.

24. Kannan R, Singh N, Przekwas A, Zhou X, Walenga R, and Babiskin A. *A Quasi-3D Model of the Whole Lung: Airway Extension to the Tracheobronchial Limit Using the Constrained Constructive Optimization and Alveolar Modeling, Using a Sac-trumpet Model*. *Journal of Computational Design and Engineering*. (2021) 8(2): 691-704. <https://doi.org/10.1093/jcde/qwab008>. PMID: [34046370](https://pubmed.ncbi.nlm.nih.gov/34046370/).
25. Kolanjiyil A, Hosseini S, Alfaifi A, Hindle M, Golshahi L, and Longest W. *Importance of Cloud Motion and Two-way Momentum Coupling in the Transport of Pharmaceutical Nasal Sprays*. *Journal of Aerosol Science*. 156. <https://doi.org/10.1016/j.jaerosci.2021.105770>.
26. Korang-Yeboah M, Ketcham S, Shih M, Ako-Adounvo A, Zhang J, Bandaranayake B, Abbey-Berko Y, Faustino P, and Ashraf M. *Effect of Formulation and Peptide Folding on the Fibrillar Aggregation, Gelation, and Oxidation of a Therapeutic Peptide*. *International Journal of Pharmaceutics*. (2021) 604. <https://doi.org/10.1016/j.ijpharm.2021.120677>. PMID: [33961953](https://pubmed.ncbi.nlm.nih.gov/33961953/).
27. Kuzma B, Senemar S, Ramezanli T, Ghosh P, Raney S, and Stagni G. *Evaluation of Local Bioavailability of Metronidazole from Topical Formulations Using Dermal Microdialysis: Preliminary Study in a Yucatan Mini-pig Model*. *European Journal of Pharmaceutical Sciences*. (2021) 159. <https://doi.org/10.1016/j.ejps.2021.105741>. PMID: [33540039](https://pubmed.ncbi.nlm.nih.gov/33540039/).
28. Lee J, Feng K, Xu M, Gong X, Sun W, Kim J, Zhang Z, Wang M, Fang L, and Zhao L. *Applications of Adaptive Designs in Generic Drug Development*. *Clinical Pharmacology and Therapeutics*. (2021) 11(1): 32-35. <https://doi.org/10.1002/cpt.2050>. PMID: [32940349](https://pubmed.ncbi.nlm.nih.gov/32940349/).
29. Lee J, Gong Y, Bhoopathy S, Diliberti C, Hooker A, Rostami-Hodjegan A, Schmidt S, Suarez-Sharp S, Lukacova V, Fang L, and Zhao L. *Public Workshop Summary Report on FY2021 Generic Drug Regulatory Science Initiatives: Data Analysis and Model-Based Bioequivalence*. *Clinical Pharmacology and Therapeutics*. (2021) 110(5): 1190-1195. <https://doi.org/10.1002/cpt.2120>. PMID: [33236362](https://pubmed.ncbi.nlm.nih.gov/33236362/).
30. Lemerdy M, Spires J, Lukacova V, Tan M, Babiskin A, Xu X, Zhao L, and Bolger M. *Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations*. *Pharmaceutical Research*. 37(12): 245. <https://doi.org/10.1007/s11095-020-02965-y>. PMID: [33215336](https://pubmed.ncbi.nlm.nih.gov/33215336/).
31. Li T, Chandrashekar A, Beig A, Walker J, Hong J, Benet A, Kang J, Ackermann R, Wang Y, Qin B, Schwendeman A, and Schwendeman S. *Characterization of Attributes and In Vitro Performance of Exenatide-Loaded PLGA Long-Acting Release Microspheres*. *European Journal of Pharmaceutics and Biopharmaceutics*. (2021) 158: 401-409. <https://doi.org/10.1016/j.ejpb.2020.10.008>. PMID: [33122118](https://pubmed.ncbi.nlm.nih.gov/33122118/).
32. Liu X, Anissimov Y, Grice J, Cheruvu H, Ghosh P, Raney S, Maibach H, and Roberts M. *Relating Transdermal Delivery Plasma Pharmacokinetics with In Vitro Permeation Test (IVPT) Findings Using Diffusion and Compartment-In-Series Models*. *Journal of Controlled Release*. (2021) 334: 37-51. <https://doi.org/10.1016/j.jconrel.2021.04.010>. PMID: [33857564](https://pubmed.ncbi.nlm.nih.gov/33857564/).
33. Liu X, Sulaiman M, Kolehmainen J, Ozel A, and Sundaresan S. *Particle-based Coarse-grained Approach for Simulating Dry Powder Inhaler*. *International Journal of Pharmaceutics*. 606. <https://doi.org/10.1016/j.ijpharm.2021.120821>. PMID: [34171427](https://pubmed.ncbi.nlm.nih.gov/34171427/).
34. Loingeville F, Bertrand J, Nguyen T, Sharan S, Feng K, Sun W, Han J, Grosser S, Zhao L, Fang L, Mollenhoff K, Dette H, and Mentre F. *New Model-Based Bioequivalence Statistical Approaches for Pharmacokinetic Studies with Sparse Sampling*. *The AAPS Journal*. (2020) 22(6): 141. <https://doi.org/10.1208/s12248-020-00507-3>. PMID: [33125589](https://pubmed.ncbi.nlm.nih.gov/33125589/).
35. Luke M, and Kozak D. *Regulating Generic Ophthalmologic Drug Bioequivalence—Envisioning Accessibility for Patients*. *Journal of Ocular Pharmacology and Therapeutics*. (2021) 37(3): 157-161. <https://doi.org/10.1089/jop.2020.0041>. PMID: [33332225](https://pubmed.ncbi.nlm.nih.gov/33332225/).
36. Manniello M, Hosseini S, Alfaifi A, Esmaeili A, Kolanjiyil A, Walenga R, Babiskin A, Sandell D, Mohammadi R, Schuman T, Hindle M, and Golshahi L. *In Vitro Evaluation of Regional Nasal Drug Delivery Using Multiple Anatomical Nasal Replicas of Adult Human Subjects and Two Nasal Sprays*.

- International Journal of Pharmaceutics. (2021) 593. <https://doi.org/10.1016/j.ijpharm.2020.120103>. PMID: [33242586](https://pubmed.ncbi.nlm.nih.gov/33242586/).
37. Mekjaruskul C, Berings A, Luo W, Xu Q, Halquist M, Qin B, Wang Y, and Lu X. *Impact of Membranes on In Vitro Release Assessment: a Case Study Using Dexamethasone*. AAPS PharmSciTech. (2021) 22(1): 42. <https://doi.org/10.1208/s12249-020-01874-y>. PMID: [33426616](https://pubmed.ncbi.nlm.nih.gov/33426616/).
  38. Meng T, Kosmider L, Chai G, Raynold A, Pearcy A, Qin B, Wang Y, Lu X, Halquist M, and Xu Q. *LC-MS/MS Method for Simultaneous Quantification of Dexamethasone and Tobramycin in Rabbit Ocular Biofluids*. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences. (2021) 1170. <https://doi.org/10.1016/j.jchromb.2021.122610>. PMID: [33713949](https://pubmed.ncbi.nlm.nih.gov/33713949/).
  39. Mitra A, Suarez-Sharp S, Pepin X, Flanagan T, Zhao Y, Kotzagiorgis E, Parrott N, Sharan S, Tistaert C, Heimbach T, Zolnik B, Sjogren E, Wu F, Anand O, Kakar S, Li M, Veerasingham S, Kijima S, Santos G, Ning B, Raines K, Rullo G, Mandula H, Delvadia P, Dressman J, Dickinson P, and Babiskin A. *Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to Support Drug Product Quality: A Workshop Summary Report*. Journal of Pharmaceutical Sciences. (2021) 110(2): 594-609. <https://doi.org/10.1016/j.xphs.2020.10.059>. PMID: [33152375](https://pubmed.ncbi.nlm.nih.gov/33152375/).
  40. O'brien M, Jiang W, Wang Y, and Loffredo D. *Challenges and Opportunities in the Development of Complex Generic Long-Acting Injectable Drug Products*. Journal of Controlled Release. (2021) 336: 144-158. <https://doi.org/10.1016/j.jconrel.2021.06.017>. PMID: [34126170](https://pubmed.ncbi.nlm.nih.gov/34126170/).
  41. Park K, Otte A, Sharifi F, Garner J, Skidmore S, Park H, Jhon Y, Qin B, and Wang Y. *Formulation Composition, Manufacturing Process, and Characterization of Poly(lactide-co-glycolide) Microparticles*. Journal of Controlled Release. (2021) 329: 1150-1161. <https://doi.org/10.1016/j.jconrel.2020.10.044>. PMID: [33148404](https://pubmed.ncbi.nlm.nih.gov/33148404/).
  42. Park K, Otte A, Sharifi F, Garner J, Skidmore S, Park H, Jhon Y, Qin B, and Wang Y. *Potential Roles of the Glass Transition Temperature of PLGA Particles in Drug Release Kinetics*. Molecular Pharmaceutics. 18(1): 18-32. <https://doi.org/10.1021/acs.molpharmaceut.0c01089>. PMID: [33331774](https://pubmed.ncbi.nlm.nih.gov/33331774/).
  43. Parrott N, Suarez Sharp S, Kesisoglou F, Pathak S, Good D, Wagner C, Dallmann A, Mullin J, Patel N, Riedmaier A, Mitra A, Raines K, Butler J, Kakhi M, Li M, Zhao Y, Tsakalozou E, Flanagan T, Dressman J, and Pepin X. *Best Practices in the Development and Validation of Physiologically Based Biopharmaceutics Modeling. A Workshop Summary Report*. Journal of Pharmaceutical Sciences. (2021) 110(2): 584-593. <https://doi.org/10.1016/j.xphs.2020.09.058>. PMID: [33058891](https://pubmed.ncbi.nlm.nih.gov/33058891/).
  44. Patel D, Zhang Y, Dong Y, Qu H, Kozak D, Ashraf M, and Xu X. *Adaptive Perfusion: An In Vitro Release Test (IVRT) for Complex Drug Products*. Journal of Controlled Release. (2021) 333: 65-75. <https://doi.org/10.1016/j.jconrel.2021.03.024>. PMID: [33766693](https://pubmed.ncbi.nlm.nih.gov/33766693/).
  45. Patel S, Greene A, Desai S, Rothstein S, Basha I, Macpherson J, Wang Y, Zou Y, Shehabeldbin M, Sfeir C, Little S, and Rohan L. *Biorelevant and Screening Dissolution Methods for Minocycline Hydrochloride Microparticles Intended for Periodontal Administration*. International Journal of Pharmaceutics. 596. <https://doi.org/10.1016/j.ijpharm.2021.120261>. PMID: [33486044](https://pubmed.ncbi.nlm.nih.gov/33486044/).
  46. Patere S, Newman B, Wang Y, Choi S, Mekjaruskul C, Jay M, and Lu X. *Influence of In Vitro Release Methods on Assessment of Tobramycin Ophthalmic Ointments*. International Journal of Pharmaceutics. (2020) 590. <https://doi.org/10.1016/j.ijpharm.2020.119938>. PMID: [33011250](https://pubmed.ncbi.nlm.nih.gov/33011250/).
  47. Patil S, Qin B, Wang Y, Ahmed S, Yilmaz H, Jiang X, Keire D, and Chen K. *A Real-Time NMR Method for Measurement of In Vitro Aggregation Kinetics of Degarelix Drug Products*. AAPS PharmSciTech. (2021) 22(2): 73. <https://doi.org/10.1208/s12249-021-01948-5>. PMID: [33586081](https://pubmed.ncbi.nlm.nih.gov/33586081/).
  48. Pawar G, Wu F, Zhao L, Fang L, Burckart G, Feng K, Mousa Y, Naumann F, and Batchelor H. *Development of a Pediatric Relative Bioavailability/Bioequivalence Database and Identification of Putative Risk Factors Associated With Evaluation of Pediatric Oral Products*. The AAPS Journal. 23(3): 57. <https://doi.org/10.1208/s12248-021-00592-y>. PMID: [33884497](https://pubmed.ncbi.nlm.nih.gov/33884497/).

49. Raofi S, Kinjo M, Sun D, Li Z, Boyce H, Natarajan K, Frost M, Zhao L, Luke M, Lionberger R, Kelsh D, and Kim M. *Particle Size Affects Pharmacokinetics of Milled Oxycodone Hydrochloride Tablet Products Following Nasal Insufflation in Nondependent, Recreational Opioid Users*. *Clinical and Translational Science*. (2021) 14(5): 1977-1987. <https://doi.org/10.1111/cts.13053>. PMID: [33982418](https://pubmed.ncbi.nlm.nih.gov/33982418/).
50. Roberts M, Cheruvu M, Mangion S, Alinaghi A, Benson H, Mohammed Y, Holmes A, Van Der Hoek J, Pastore M, and Grice J. *Topical Drug Delivery: History, Percutaneous Absorption, and Product Development*. *Advanced Drug Delivery Reviews*. 177. <https://doi.org/10.1016/j.addr.2021.113929>. PMID: [34403750](https://pubmed.ncbi.nlm.nih.gov/34403750/).
51. Sharan S, Fang L, Lukacova V, Chen X, Hooker A, and Karlsson M. *Model-Informed Drug Development for Long-Acting Injectable Products: Summary of American College of Clinical Pharmacology Symposium*. *Clinical Pharmacology in Drug Development*. 10(3): 220-228. <https://doi.org/10.1002/cpdd.928>. PMID: [33624456](https://pubmed.ncbi.nlm.nih.gov/33624456/).
52. Sharan S, Wang Y, Donnelly M, Zou Y, Fang L, Kim M, and Zhao L. *Regulatory Science to Promote Access to Intrauterine Systems for Women in the United States*. *The Journal of Clinical Pharmacology*. 60(S2): S34-S38. <https://doi.org/10.1002/jcph.1710>. PMID: [33274507](https://pubmed.ncbi.nlm.nih.gov/33274507/).
53. Shi Y, Ren P, Zhang Y, Gong X, Hu M, and Liang H. *Information Extraction from FDA Drug Labeling to Enhance Product-Specific Guidance Assessment Using Natural Language Processing*. *Frontiers in Research Metrics and Analytics*. (2021) 6: Article 670006. <https://doi.org/10.3389/frma.2021.670006>. PMID: [34179681](https://pubmed.ncbi.nlm.nih.gov/34179681/).
54. Shin S, Rantou E, Raney S, Ghosh P, Hassan H, and Stinchcomb A. *Cutaneous Pharmacokinetics of Acyclovir Cream 5% Products: Evaluating Bioequivalence with an In Vitro Permeation Test and an Adaptation of Scaled Average Bioequivalence*. *Pharmaceutical Research*. 37(10): 210. <https://doi.org/10.1007/s11095-020-02821-z>. PMID: [33001286](https://pubmed.ncbi.nlm.nih.gov/33001286/).
55. Singh G, Lowe A, Azeem A, Cheng S, Chan H, Walenga R, and Kourmatzis A. *Effect of Inflow Conditioning for Dry Powder Inhalers*. *International Journal of Pharmaceutics*. 608. <https://doi.org/10.1016/j.ijpharm.2021.121085>. PMID: [34508843](https://pubmed.ncbi.nlm.nih.gov/34508843/).
56. Smith W, Bae J, Zhang Y, Qin B, Wang Y, Kozak D, Ashraf M, and Xu X. *Impact of Particle Flocculation on the Dissolution and Bioavailability of Injectable Suspensions*. *International Journal of Pharmaceutics*. (2021) 604. <https://doi.org/10.1016/j.ijpharm.2021.120767>. PMID: [34087414](https://pubmed.ncbi.nlm.nih.gov/34087414/).
57. Suh M, Kastellorizios M, Tipnis N, Zou Y, Wang Y, Choi S, and Burgess D. *Effect of Implant Formation on Drug Release Kinetics of In Situ Forming Implants*. *International Journal of Pharmaceutics*. (2021) 592. <https://doi.org/10.1016/j.ijpharm.2020.120105>. PMID: [33232755](https://pubmed.ncbi.nlm.nih.gov/33232755/).
58. Thomas B, Absar M, Delvadia R, Conti D, Witzmann K, and Guo C. *Analytical Method Development for Characterizing Ingredient-Specific Particle Size Distributions of Nasal Spray Suspension Products*. *Journal of Pharmaceutical Sciences*. 110(7): 2778-2788. <https://doi.org/10.1016/j.xphs.2021.03.005>. PMID: [33713688](https://pubmed.ncbi.nlm.nih.gov/33713688/).
59. Thomas C, Mosley S, Kim S, Lingineni K, Rouby N, Langae T, Gong Y, Wang D, Schmidt S, Binkley P, Estores D, Feng K, Kim H, Kinjo M, Li Z, Fang L, Chapman A, Cooper-Dehoff R, Gums J, Hamadeh I, Zhao L, Schmidt S, Frye R, Johnson J, and Cavallari L. *Examination of Metoprolol Pharmacokinetics and Pharmacodynamics across CYP2D6 Genotype-Derived Activity Scores*. *CPT Pharmacometrics & Systems Pharmacology*. (2020) 9(12): 687-685. <https://doi.org/10.1002/psp4.12563>. PMID: [33067866](https://pubmed.ncbi.nlm.nih.gov/33067866/).
60. Toropainen E, Fraser-Miller S, Novakovic D, Del Amo E, Vellonen K, Ruponen M, Viitala T, Korhonen O, Auriola S, Hellinen L, Reinisalo M, Tengvall U, Choi S, Absar M, Strachan C, and Urtti A. *Biopharmaceutics of Topical Ophthalmic Suspensions: Importance of Viscosity and Particle Size in Ocular Absorption of Indomethacin*. *Pharmaceutics*. (2021) 13(4): 452. <https://doi.org/10.3390/pharmaceutics13040452>. PMID: [33810564](https://pubmed.ncbi.nlm.nih.gov/33810564/).

61. Tsakalozou E, Alam K, Babiskin A, and Zhao L. *Physiologically-Based Pharmacokinetic Modeling to Support Determination of Bioequivalence for Dermatological Drug Products: Scientific and Regulatory Considerations*. *Clinical Pharmacology and Therapeutics*. (2021). <https://doi.org/10.1002/cpt.2356>. PMID: [34231211](https://pubmed.ncbi.nlm.nih.gov/34231211/).
62. Tsakalozou E, Babiskin A, and Zhao L. *Physiologically-Based Pharmacokinetic Modeling to Support Bioequivalence and Approval of Generic Products: A Case for Diclofenac Sodium Topical Gel, 1%*. *CPT: Pharmacometrics & Systems Pharmacology*. (2021) 10(5): 399-411. <https://doi.org/10.1002/psp4.12600>. PMID: [33547863](https://pubmed.ncbi.nlm.nih.gov/33547863/).
63. Vo A, Feng X, Smith W, Zhu D, Patel M, Kozak D, Wang Y, Zheng J, Ashraf M, and Xu X. *Analyzing Ophthalmic Suspension Particle Size Distributions using Laser Diffraction: Placebo Background Subtraction Method*. *International Journal of Pharmaceutics*. (2021) 598: 120401. <https://doi.org/10.1016/j.ijpharm.2021.120401>. PMID: [33636327](https://pubmed.ncbi.nlm.nih.gov/33636327/).
64. Walenga R, Dhapare S, Newman B, Babiskin A, and Zhao L. *In Silico and Experimental Methods to Support Generic Nasal Drug Product (NDP) Development*. *Respiratory Drug Delivery*. 1: 141-150.
65. Wan B, Andhariya J, Bao Q, Wang Y, Zou Y, and Burgess D. *Effect of Polymer Source on In Vitro Drug Release from PLGA Microspheres*. *International Journal of Pharmaceutics*. 607. <https://doi.org/10.1016/j.ijpharm.2021.120907>. PMID: [34332059](https://pubmed.ncbi.nlm.nih.gov/34332059/).
66. Wang Y, Qin B, Xia G, and Choi S. *FDA's Poly (Lactic-Co-Glycolic Acid) Research Program and Regulatory Outcomes*. *AAPS Journal*. (2021) 23(4): 92. <https://doi.org/10.1208/s12248-021-00611-y>. PMID: [34189655](https://pubmed.ncbi.nlm.nih.gov/34189655/).
67. Wu F, Cristofolletti R, Zhao L, and Rostami-Hodjegan A. *Scientific Considerations to Move Towards Biowaiver for Biopharmaceutical Classification System Class III Drugs: How Modeling and Simulation Can Help*. *Biopharmaceutics & Drug Disposition*. (2021) 42(4): 118-127. <https://doi.org/10.1002/bdd.2274>. PMID: [33759204](https://pubmed.ncbi.nlm.nih.gov/33759204/).
68. Zhao L, Li Z, Fang L, Kim M, Nallani S, Sahajwalla C, Calderon S, Roca R, Feng K, Zineh I, and Lionberger R. *Association of Partial Systemic Exposure and Abuse Potential for Opioid Analgesics with Abuse Deterrence Labeling Claims Supporting Product-Specific Guidance*. *EClinicalMedicine*. 41. <https://doi.org/10.1016/j.eclinm.2021.101135>. PMID: [34585126](https://pubmed.ncbi.nlm.nih.gov/34585126/).